Abstract
I report a case of hypotension and bradycardia before spinal anesthesia in a pregnant woman with mild to moderate hypertension treated with nifedipine and methyldopa, scheduled for an elective cesarean delivery. She had the history of neurally-mediated syncopes. Two main factors (increased vagal tone and adverse effects of antihypertensive drugs) could explain the hypotension and bradycardia before spinal anesthesia. Monitoring allowed recognizing the problem and corrected it. Thus, it was avoided a disaster in anesthesia, as hemodynamic changes after spinal anesthesia, they would have joined to previous hypotension and bradycardia, which would have caused even a cardiac arrest.
KEYWORDS
Hypotension; Bradycardia; Vagal tone; Antihypertensives drugs
Resumo
Relato de um caso de hipotensão e bradicardia antes da raquianestesia em uma mulher grávida com hipertensão leve a moderada tratada com nifedipina e metildopa, programada para parto cesáreo eletivo. A paciente apresentava história de síncopes neuralmente mediadas. Dois fatores principais (aumento do tônus vagal e efeitos adversos de medicamentos anti-hipertensivos) poderiam explicar a hipotensão e bradicardia antes da raquianestesia. O monitoramento permitiu reconhecer o problema e corrigi-lo. Dessa forma, foi evitado um desastre em anestesia; assim como as alterações hemodinâmicas após a raquianestesia, esses fatores teriam se juntado à hipotensão e bradicardia anterior, o que poderia até ter causado uma parada cardíaca.
PALAVRAS-CHAVE
Hipotensão; Bradicardia; Tônus vagal; Medicamentos anti-hipertensivos
Introduction
A wide range of antihypertensive drugs have been proposed to decrease the blood pressure in hypertensive pregnant women, and each of them has different side effects and potential adverse effects. There is no consensus about the definition of hypertensive pregnancy disorders and several classifications have been suggested. Variations in the systems for classification are largely according to which values of blood pressure are considered abnormal. Nevertheless, there is currently an agreement regarding the existence of four categories which include gestational hypertension or pregnancy-induced hypertension.11 Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014, http://dx.doi.org/10.1002/14651858.CD002252.pub3. Art. No. CD002252.
http://dx.doi.org/10.1002/14651858.CD002...
A case of hypotension and bradycardia before spinal anesthesia in a pregnant woman with mild to moderate hypertension, scheduled for an elective cesarean delivery, is reported with the patient's and the Hospital Ethics Committee's written consent.
Case report
A 34-year-old patient was admitted four days before surgery, with a gestational age of 37 weeks by date of last menstruation and pregnancy-induced hypertension. She had two previous Caesarian sections (in 2007 and 2011) which were performed with spinal anesthesia without complications. She was suffering from intermittent bronchial asthma, with a final episode in the year 2013; and reported some episodes of vasovagal and orthostatic syncopes in different times of her life. Her weight and height were 98.8 kg and 1.65 m, respectively. Her physical condition was grade 2 according to American Society Anesthesiologists physical status classification; she was assigned to class 2 of Goldman index of cardiac risk and had a normal electrocardiogram. The laboratory analyses showed a hemogram with normal values (hematocrit 41%, platelets 237,000 mm3); the values of glucose, creatinine, urea, and aminotransferases were normal too. The value of proteins in a 24 h urine was 126 mg (3000 mL of urinary volume).
When the patient was hospitalized, four days before the surgery, her blood pressure was 140/80 mmHg and the heart rate (HR) was 79 beats per minute (bpm). An antihypertensive treatment of 10 mg of nifedipine was administered orally t.i.d. A day later was added methyldopa 500 mg orally t.i.d. She swallowed food until 5 p.m. and received the last dose of antihypertensive drugs up to 22 h of the previous day to the cesarean section.
The day of surgery the patient did not receive antihypertensive treatment, and the last control of vital signs at 7 a.m. was registered as normal in the hospitalization area. Furthermore, she received a bolus of physiological saline serum (500 mL). None of the previous controls of blood pressure was lesser than 110/70 mmHg until two days before the cesarean section. However the day before, she registered a blood pressure of 90/60 mmHg at 1 p.m.
When the patient entered the operating room at 9:40 a.m., she was lucid and oriented; nevertheless, paleness and anxiety were observed. A non-invasive blood pressure (NIBP) of 73/35 mmHg was measured in the multi-parameters monitor, HR of 37 bpm and a breathing rate of 18 breaths per minute. The results were corroborated by manual measurements. The patient was asked if she had taken some medicine which she denied.
The patient received an infusion of 500 mL of isotonic saline solution; next a NIBP of 80/42 mmHg was measured. After she was given 1000 mL, her NIBP was 92/64 mmHg. Finally, she gave a volume of 1500 mL and her blood pressure rose to 110/60 mmHg. Atropine (0.5 mg) was given intravenously, which made her HR go up to 82 bpm. At 10 am, I proceeded to administer spinal anesthesia containing 10 mg of hyperbaric Bupivacaine and 10 µgr of fentanyl, at the level of the L3-L4 space with needle type Quincke no. 26. We placed the patient in dorsal decubitus with 15° of left inclination from the surgical table. Fifteen minutes after, the surgery started with a NIBP of 90/42 mmHg and HR of 114 bpm. Ten minutes after there was the birth of the fetus with good Apgar scores; in this time it was controlled a NIBP of 79/40 mmHg, so I started intravenous infusion of 3 mg of Etilefrine and two bolus of 1 mg of the same drug with that the NIBP rose to 130/60 mmHg.
No other problems occurred in the remaining period of the surgery. The patient left at 11:05 with isotonic saline solution (total infused volume of 2500 mL) and 20 IU of Oxytocin infused intravenously, without any kind of vasopressor, NIBP of 114/64 mmHg, HR 99 bpm, oxygen saturation on room air 96% and breathing rate of 16 bpm.
Discussion
When I investigated the causes of hypotension and bradycardia at the entrance to the operating room, anaphylaxis was discarded first, because it has not had provided any medication before operating room; then, was considered an excess vagal because she had had some episodes of transient loss of consciousness tone, even though she was aware when she arrived to the operating room. Nonetheless, there are some interesting points about the adverse effects of antihypertensive drugs, too.
Nifedipine, as calcium antagonist antihypertensive, has a short terminal half-life of 1.9 h for a 10 mg tablet, so multiple doses are required to achieve the effective concentration (78 µg/lt.); being the minimum concentration to decrease diastolic pressure of 10-15 µg/lt.22 Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 1998;34:457-82. In relation to orthostatic syncopes, it has been described four causes of compensatory failure. One of them is the attenuation of vasoconstrictor response to sympathetic stimulation; this attenuated response is primarily caused by the administration of vasodilative agents among which are calcium antagonists as nifedipine.33 Iwase S, Nishimura N, Mano T. Role of sympathetic nerve activity in the process of fainting. Front Physiol. 2014;5:343, http://dx.doi.org/10.3389/fphys.2014.00343.eCollection 2014.
http://dx.doi.org/10.3389/fphys.2014.003...
Methyldopa (α-methyl-3,4-dihidroxi-l-phenylalanine), analog of 3,4-dihydroxyphenylalanine (DOPA) discovered in 1960 by Oates,44 Oates JA, Gillespie L, Udenfriend S, et al. Decarboxylase inhibition and blood pressure reduction by α-methyl-3,4-dihydroxy-dl-phenylalanine. Science. 1960;131:1890-1891. is a prodrug of central action that acts by the active metabolite α-methylnorepinephrine (which replaces norepinephrine in the secretory vesicles of adrenergic neurons). It causes a decrease of the blood pressure which is a maximum of 6-8 h after an oral or intravenous dose, and mitigates but does not block completely baroreceptors-mediated vasoconstriction. For this reason, is tolerated well during surgical anesthesia and any severe hypotension is reversible with volume expansion, as it happened with the management of this pregnant woman inside the operating room. Although the maximum plasma concentrations occur after 2-3 h, the maximum effect is delayed 6-8 h, and a single dose usually lasts almost 24 h, which allows providing a dosage one to two times per day.55 Hoffman BB. Therapy of hypertension. In: Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies Inc.; 2006. p. 845-68.
6 Van Zwieten PA, Thoolen MJ, Timmermans PB. The hypotensive activity of methyldopa, clonidine, and guanfacine. Hypertension. 1984;6(Pt 2):II28-33.-77 Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007;9:399-405. Therefore, in this case, methyldopa should not have been supplied three times per day and could have begun with one lower dose; even more considering that she was already receiving nifedipine.
Among the most common adverse effects from methyldopa include fatigue, xerostomia, decreased libido, parkinsonian signs, hyperprolactinemia, hepatotoxicity, intense bradycardia and sinoatrial asystole, sedation and even depression in higher doses.88 Engelman K. Side effects of sympatholytic antihypertensive drugs. Hypertension. 1988;11(Pt 2):II 30-3.,99 Michel T, Hoffman BB. Treatment of myocardial ischemia and hypertension. In: Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Companies Inc.; 2011. p. 745-88. Hypotension has also been reported as frequent adverse effect, especially in younger patients, lighter subjects, patients with impairment of renal function or in those taking high daily doses.1010 Lawson DH, Gloss D, Jick H. Adverse reaction to methyldopa with particular reference to hypotension. Am Heart J. 1978;96:572-9. However, it has a safety profile in the treatment of gestational hypertension, currently reaching to constitute the drug of choice for the treatment of non-severe hypertension in this population, used in different regions around the world.55 Hoffman BB. Therapy of hypertension. In: Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies Inc.; 2006. p. 845-68.,1111 Al Khaja KA, Sequeira RP, Alkhaja AK, et al. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32:454-63.
12 Xie RH, Guo Y, Krewski D, et al. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. Eur J Obstet Gynecol Reprod Biol. 2013;171:281-5.-1313 Stocks G. Preeclampsia: pathophysiology, old and new strategies for management. Eur J Anaesthesiol. 2014;31:183-9.
In conclusion, two main factors can be observed in this case, in one side a history of increased vagal tone of the patient and in the other, the adverse effects of previous medical therapy. Both of them affected the planned anesthetic scheme for an elective surgery. Monitoring had an important role because it allowed recognizing the problem and corrected it. Thus, it was avoided a disaster in anesthesia, as hemodynamic changes that occur after a spinal anesthesia in a pregnant woman, they would have joined to previous hypotension and bradycardia, which probably would have caused even a cardiac arrest.
Acknowledgements
Assistance with the case: the author would like to express his sincere gratitude to Jacpar E. Diaz, MD, for his help with the references; and to Katherine Sandoval, Intern of Medicine, for her help to make the home interview of the patient.
References
-
1Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014, http://dx.doi.org/10.1002/14651858.CD002252.pub3 Art. No. CD002252.
» http://dx.doi.org/10.1002/14651858.CD002252.pub3 -
2Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 1998;34:457-82.
-
3Iwase S, Nishimura N, Mano T. Role of sympathetic nerve activity in the process of fainting. Front Physiol. 2014;5:343, http://dx.doi.org/10.3389/fphys.2014.00343.eCollection 2014.
» http://dx.doi.org/10.3389/fphys.2014.00343.eCollection -
4Oates JA, Gillespie L, Udenfriend S, et al. Decarboxylase inhibition and blood pressure reduction by α-methyl-3,4-dihydroxy-dl-phenylalanine. Science. 1960;131:1890-1891.
-
5Hoffman BB. Therapy of hypertension. In: Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies Inc.; 2006. p. 845-68.
-
6Van Zwieten PA, Thoolen MJ, Timmermans PB. The hypotensive activity of methyldopa, clonidine, and guanfacine. Hypertension. 1984;6(Pt 2):II28-33.
-
7Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007;9:399-405.
-
8Engelman K. Side effects of sympatholytic antihypertensive drugs. Hypertension. 1988;11(Pt 2):II 30-3.
-
9Michel T, Hoffman BB. Treatment of myocardial ischemia and hypertension. In: Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Companies Inc.; 2011. p. 745-88.
-
10Lawson DH, Gloss D, Jick H. Adverse reaction to methyldopa with particular reference to hypotension. Am Heart J. 1978;96:572-9.
-
11Al Khaja KA, Sequeira RP, Alkhaja AK, et al. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32:454-63.
-
12Xie RH, Guo Y, Krewski D, et al. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. Eur J Obstet Gynecol Reprod Biol. 2013;171:281-5.
-
13Stocks G. Preeclampsia: pathophysiology, old and new strategies for management. Eur J Anaesthesiol. 2014;31:183-9.
Publication Dates
-
Publication in this collection
Sep-Oct 2017
History
-
Received
26 Nov 2014 -
Accepted
2 Dec 2014